FDA/CDC

FDA approves Rebinyn for hemophilia B treatment

Publish date: June 2, 2017
By
Lucas Franki

 

The Food and Drug Administration has approved Rebinyn (nonacog beta pegol, N9-GP) for the treatment of hemophilia B, according to a statement from Novo Nordisk.

Caused by deficient blood clotting factor IX activity, hemophilia B affects about 5,000 people in the United States. The disease is chronic and inherited and causes prolonged and spontaneous bleeding, particularly into muscles, joints, or internal organs. Rebinyn is intended to control and treat bleeding episodes, as well as provide perioperative management of bleeding.

The FDA has approved Rebinyn for both adult and pediatric patients, based on results from clinical trials comprising 115 hemophilia B patients. The most common side effects are swelling, pain, rash, or redness at the location of infusion and itching.

Find the full statement about Rebinyn’s approval on the Novo Nordisk website.

Recommended Reading

Planning, education smooth transition to longer-acting clotting factors
MDedge Pediatrics
Calcium channel blocker reduces cardiac iron loading in thalassemia major
MDedge Pediatrics
Factor VIII microcapsules eyed for eluding neutralizing antibodies
MDedge Pediatrics
VIDEO: Hemophilia B gene therapy maintains factor IX levels averaging 28%
MDedge Pediatrics
Study: No link between vaccines, inhibitor development
MDedge Pediatrics
Boys with severe hemophilia have good physical function
MDedge Pediatrics
Safety of N9-GP for hemophilia B needs further study, FDA committee agrees
MDedge Pediatrics
DTC genetic health risk tests: Beware
MDedge Pediatrics
Watchful waiting a suitable option for pediatric acute ITP
MDedge Pediatrics
FDA advisory committee supports L-glutamine for SCD
MDedge Pediatrics